PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

Israeli blood test detects early breast cancer with 95% accuracy

Israeli researchers developed a blood test that detects early breast cancer with 95% accuracy and predicts recurrence risk using epigenetic signatures on cell-free nucleosomes.

13sources
13articles
12velocity
+486%since first seen
6d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

The coverage highlighted the test's ability to identify a nucleosome epigenetic signature linked to diagnosis and prognosis. No subsequent headlines indicate further clinical validation, regulatory steps, or implementation updates after the initial study announcement.

Epilogue added 2d ago, after coverage quieted.

The brief

The research, led by scientists at the Hebrew University of Jerusalem and Hadassah Medical Center, uses an epigenetic liquid biopsy approach that profiles histone modifications on cell-free nucleosomes circulating in blood.

The study extensively profiled epigenetic heterogeneity in treatment-naive human luminal breast tumours obtained directly after surgical resection. Using a single-cell epigenetic approach based on cytometry by time-of-flight, researchers identified a recurrent subpopulation of basal-like cells within luminal tumours that carries a conserved epigenetic signature across patients. These basal-like cells, also identified through deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling.

Direct comparison of single-cell proteomic and genomic profiling revealed that monomethylation and trimethylation of histone 3 on lysine 4 (H3K4me1 and H3K4me3) are key features associated with loss of luminal identity. The researchers highlighted the potential of concomitant single-molecule profiling of these histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, enabling identification of patients at increased risk for disease relapse.

Breast cancer remains the most diagnosed cancer among women and is stratified by gene expression patterns into luminal and basal-like subtypes, with basal-like associated with worse prognosis. Recent advances in single-cell technologies have underscored intratumour heterogeneity, which poses substantial challenges for treatment and long-term disease-free survival. The new test addresses this by detecting the epigenetic signature of aggressive basal-like cells that may be present even in luminal tumours, potentially catching hidden threats that could cause cancer to return.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (91% supported) Updated 4d ago.

Quick answers

What is the accuracy rate of the new Israeli blood test for detecting early breast cancer?

The blood test detects early breast cancer with 95% accuracy, according to the study published in Nature and reported by The Times of Israel.

How does the blood test predict breast cancer recurrence?

The test measures an epigenetic basal signature on cell-free nucleosomes in blood, which is linked to prognosis and enables identification of patients at increased risk for disease relapse.

What epigenetic markers does the test analyze?

The test profiles histone modifications on cell-free nucleosomes, specifically monomethylation and trimethylation of histone 3 on lysine 4 (H3K4me1 and H3K4me3), which are key features associated with loss of luminal identity in breast tumours.

Coverage (13)

Topics

Related trends

↑ Rising Business

Permitting Bill Would Charge Data Centers Billions for Power

A new Harvard study reveals 400 U.S. hyperscale data centers now consume electricity equal to entire states like Michigan, while a permitting bill proposes charging operators billions for power infrastructure.

9 sources 9 articles v 34 1d ago
\n \n \n \n \n \n \n